The #AIEye: IBM (NYSE: $IBM) Launches #AI-Powered BTI
and Accenture (NYSE: $ACN) Doubles Size of DC Digital Studio
AI in Life Sciences to Grow at CAGR of 21.1% from
2019-2024
Point Roberts WA, Vancouver BC – May 14,
2019 – Investorideas.com (www.investorideas.com), a global investor news source
covering Artificial Intelligence (AI)
brings you today’s edition of The
AI Eye- watching stock
news, deal tracker and advancements in artificial intelligence.
Listen
to today’s podcast:
Read
this in full at https://www.investorideas.com/news/2019/artificial-intelligence/05141AIEye-IBM-ACN.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence
Stocks
discussed: (NYSE:IBM) (NYSE:ACN)
IBM (NYSE:IBM) today launched
its Business Transactional Intelligence (BTI). According to the press release,
BTI is “an AI-powered solution that offers anomaly detection and visualization
capabilities for mitigating supply chain disruptions and accelerating
data-driven decision making”. Connie Rekau, EDI [electronic data interchange]
Manager, The Master Lock Company, explains:
"With IBM Business Transaction
Intelligence, we can dig deeper into our EDI data to identify patterns that
wouldn't otherwise be obvious. As well as building a scorecard to track our
performance against internal service-level level agreements [SLAs] with the
business, we have set up reports that highlight trading partners with
higher-than-average error rates."
Accenture (NYSE:ACN) has announced a doubling of the
size of its Accenture Federal Digital Studio in Washington, D.C., making the
facility over 20,000 square feet and increasing the size its the team as well.
The Studio helps clients create digital solutions through the use of AI and
analytics. John Goodman, CEO of Accenture Federal Services (AFS), said:
“Our
newly expanded Studio will help government leaders gain new perspectives,
embrace new technologies faster, adopt successful approaches from the private
sector, and activate them for the good of our society and our nation.”
AI
in Life Sciences to Grow at CAGR of 21.1% from 2019-2024
A report recently published on Industry Research finds that the AI in Life
Sciences Market, currently valued at $902.1 million USD, is projected to
exhibit a compound annual growth rate (CAGR) of 21.1 percent from 2019 to 2024.
An excerpt from the report description reads:
As
AI operates on large sets of data, the availability of such data becomes a key
factor for establishing a suitable environment for the growth of AI-based
solutions. With innovations in mobile technology and sensors, even the present
day's wearables like smartwatches and fitness trackers, have enough computing
power to generate and process vast amounts of data.
In
fact, according to the recent estimates of Consumer Technology Association, a
prominent standard and trade organization for the consumer electronics industry
based in the United States, health and fitness trackers accounted for more than
47% of the wearables devices sold in 2017. This scenario coupled with several
medical devices used in healthcare sector generates huge sets of data that
could make use of AI to derive useful results.
AI
is increasingly becoming popular in drug discovery, personalized medicine,
biotechnology, and clinical trials. With increasing healthcare spending in
almost all parts of the world, the pharmaceutical industry has been involved in
extreme R&D activities in the past few years.
Sam Mowers, Investorideas.com
For
a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member
About Investorideas.com -
News that Inspires Big Investing Ideas Investorideas.com
is a recognized news source publishing third party news and press releases plus
we create original financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto
Corner and Podcast, Play by Play sports and stock
news column, Investor
Ideas #Potcasts #Cannabis News and Stocks
on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast
and column covering developments in AI.
The
Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com,
iHeartRadio and Google Play Music.
Visit
the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding specific
questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The
AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment